Table 1: Clinical and demographic features of the study population before CT-scan.
PE |
present (n = 9) |
non-present (n = 39) |
p-value |
unclear (n = 4) |
||
Male: females |
3:6 (33%:67%) |
20:19 (51%:49%) |
0.176 |
4:0 (100%:0%) |
||
Age (y) |
69.4 [62.1-79.8] |
67.7 [61.8-79.0] |
0.355 |
67.8 [61.6- 72.0] |
||
Non-Caucasian race |
2 (22.2%) |
14 (35.9%) |
0.216 |
3 (75%) |
||
Risk factor: |
||||||
Wells-Score ≥ 4 |
3 (33.3%) |
15 (38.5%) |
0.393 |
3 (75%) |
||
Bed rest |
5 (55.6%) |
14 (35.9%) |
0.213 |
3 (75%) |
||
Previous VTE |
2 (22.2%) |
1 (2.6%) |
0.112 |
0 (0%) |
||
Active cancer |
2 (22.2%) |
6 (15.4%) |
0.337 |
1 (25%) |
||
Obesity |
5 (55.6%) |
25 (64.1%) |
0.333 |
1 (25%) |
||
CT-Indication: |
||||||
CT-datum after admission(d) |
15.22 [2-6] |
6 [0-5.5] |
0.121 |
14 [4-22] |
||
Respiratory worsening |
6 (66.7%) |
25 (64.1%) |
0.446 |
3 (75%) |
||
|
Low O2 Saturation on ambient air |
2 (22.2%) |
14 (35.9%) |
0.213 |
2 (50%) |
|
Dyspnoea |
3 (33.3%) |
12 (30.7%) |
0.445 |
2 (50%) |
||
|
Tachypnoea |
3 (33.3%) |
4 (10.3%) |
0.108 |
2 (50%) |
|
Intubated |
3 (33.3%) |
9 (23.1%) |
0.290 |
2 (50%) |
||
Respiratory asymptomatic |
3 (33.3%) |
14 (35.9%) |
0.446 |
0 (0%) |
||
|
Chest Pain |
0 (0.0%) |
2 (5.2%) |
0.080 |
0 (0%) |
|
Infect focus |
0 (0.0%) |
3 (7.7%) |
0.042 |
0 (0.0%) |
||
Elevated |
0 (0.0%) |
3 (7.7%) |
0.042 |
0 (0.0%) |
||
Other CT-indications |
3 (33.3%) |
6 (15.4%) |
0.167 |
0 (0%) |
||
Setting: |
||||||
Intensive Care Unit |
3 (33.3%) |
8 (20.5%) |
0.244 |
2 (50%) |
||
Intermediate Care Unit |
1 (11.1%) |
7 (17.9%) |
0.300 |
1 (25%) |
||
Standard Care Unit |
5 (55.6%) |
24 (61.5%) |
0.381 |
1 (25%) |
||
Medication |
||||||
Steroids |
5 (55.6%) |
17 (43.6%) |
0.274 |
3 (75%) |
||
Antiaggregant |
||||||
Aspirin |
1 (11.1%) |
7 (17.9%) |
0.300 |
1 (25%) |
||
Other |
0 (0%) |
4 (10.3%) |
0.022 |
0 (0%) |
||
Heparin doses |
||||||
Regular prophylactic |
0 (0%) |
6 (15.4%) |
0.006 |
1 (25%) |
||
|
Duration (in days) |
- |
7 [2.25-9.75] |
|
5 |
|
Therapeutic |
5 (55.6%) |
16 (41.0%) |
0.233 |
3 (75%) |
||
|
Duration (in days) |
22.4 [2-25] |
9.8[2-8] |
0.188 |
17 [10-25] |
|
DOAC |
1 (11.1%) |
4 (10.3%) |
0.473 |
0 (0%) |
||
D-Dimer (μg/L) |
||||||
< 500 |
0 (0%) |
0 (0%) |
0 |
0 (0%) |
||
500-1500 |
1 (11.1%) |
12 (30.8%) |
0.081 |
2 (50%) |
||
1500-4000 |
4 (44.4%) |
12 (30.8%) |
0.244 |
0 (0%) |
||
> 4000 |
1 (11.1%) |
6 (15.4%) |
0.370 |
1 (25%) |
||
Platelet < 150.000 |
2 (22.2%) |
5 (12.8%) |
0.281 |
0 (0%) |
||
Gasometry |
||||||
PaO2/FiO2 ratio (mmHg) |
||||||
< 100 |
1 (11.1%) |
3 (7.7%) |
0.390 |
0 (0%) |
||
100-200 |
1 (11.1%) |
3 (7.7%) |
0.390 |
0 (0%) |
||
> 200 |
2 (22.2%) |
12 (30.8%) |
0.307 |
3 (75%) |
||
pCO2 (mmHg) |
||||||
< 35 |
0 (0%) |
7 (17.9%) |
0.003 |
1 (25%) |
||
Infect burden on CT-Scan |
||||||
Severe |
4 (44.4%) |
14 (35.9%) |
0.333 |
2 (50%) |
||
Moderate |
0 (0.0%) |
10 (25.6%) |
< 0.05 |
2 (50%) |
||
Mild |
3 (33.3%) |
13 (33.3%) |
0.5 |
0 (0%) |
||
No infiltrate |
2 (22.2%) |
2 (5.2%) |
0.144 |
0 (0%) |